Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.

Cardiovascular disease frequently occurs after lymphoma therapy, but it is common in the general population too. Therefore, risk estimation requires comparison to population-based rates. We calculated risk by standardized incidence ratios (SIRs) and absolute excess risks (AERs) per 10,000 person-years based on general population rates (Continuous Morbidity Registry Nijmegen) in 476 (Dutch and Belgian) patients with aggressive non-Hodgkin lymphoma (NHL) treated with at least 6 cycles of doxorubicin-based chemotherapy in 4 European Organization for Research on Treatment of Cancer (EORTC) trials (1980-1999). Cumulative incidence of cardiovascular disease, estimated in a competing risk model, was 12% at 5 years and 22% at 10 years (median follow-up, 8.4 years). Risk of chronic heart failure appeared markedly increased (SIR, 5.4; 95% CI, 4.1-6.9) with an AER of 208 excess cases per 10 000 person-years, whereas risk of coronary artery disease matched the general population (SIR, 1.2; 95% CI, 0.8-1.8; AER, 8 per 10 000 person-years). Risk of stroke was raised (SIR, 1.8; 95% CI, 1.1-2.4; AER, 15 per 10 000 person-years), especially after additional radiotherapy (> 40 Gy). Preexisting hypertension, NHL at young age, and salvage treatment increased risk of all cardiovascular events; the effect of radiotherapy was dose dependent. In conclusion, patients are at long-term high risk of chronic heart failure after NHL treatment and need therefore life-long monitoring. In contrast, risk of coronary artery disease appeared more age dependent than treatment related.

[1]  J. Baars,et al.  Relative risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymphoma , 2005 .

[2]  J. Raemaekers,et al.  Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. , 2005, Clinical lymphoma & myeloma.

[3]  A. Avilés,et al.  Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy , 2005, Leukemia & lymphoma.

[4]  S. Lipsitz,et al.  Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[6]  G. Salles,et al.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Henk-Jan Guchelaar,et al.  Cardiotoxicity of cytotoxic drugs. , 2004, Cancer treatment reviews.

[8]  R. Gressin,et al.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. , 2004, The New England journal of medicine.

[9]  P. Gaulard,et al.  Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. , 2003, Blood.

[10]  C. Pepine,et al.  Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003, JAMA.

[11]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[12]  P Ducimetière,et al.  Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. , 2003, European heart journal.

[13]  E. Deconinck,et al.  Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  E. Cavallin-ståhl,et al.  A Systematic Overview of Radiation Therapy Effects in Hodgkin's Lymphoma , 2003, Acta oncologica.

[15]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[16]  A. Avilés,et al.  Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial , 2002, European journal of haematology.

[17]  H. Bartelink,et al.  Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Boland,et al.  Etude pilote pour le developpement d'un registre de l'infarctus du myocarde en region liegeoise (Belgique) , 2001 .

[19]  S. Tucker,et al.  Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. , 2001, International journal of radiation oncology, biology, physics.

[20]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[21]  Michael Gnant.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. , 2001 .

[22]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[23]  P. Poole‐Wilson,et al.  Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.

[24]  H. Kluin-Nelemans,et al.  Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. , 2001, Journal of the National Cancer Institute.

[25]  A. Avilés,et al.  Late Lethal Events in Patients with Diffuse Large B Cell Lymphoma: a Review of 714 Patients Treated in a Single Centre , 2001, Leukemia & lymphoma.

[26]  J. Reginster,et al.  [Pilot study for the registration of acute myocardial infarction in the Liège area (Belgium)]. , 2001, Revue d'epidemiologie et de sante publique.

[27]  L. Pilotto.  [Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[28]  A. Dobson,et al.  Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations , 2000, The Lancet.

[29]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[30]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[31]  S. Lipshultz,et al.  Epidemiology of anthracycline cardiotoxicity in children and adults. , 1998, Seminars in oncology.

[32]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[33]  M. Domanski,et al.  Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Kromhout,et al.  The incidence of suspected myocardial infarction in Dutch general practice in the period 1978-1994. , 1998, European heart journal.

[35]  D. Wood.  European Action on Secondary Prevention by Intervention to Reduce Events , 1998 .

[36]  P. Kaufmann,et al.  Cardiac risk after mediastinal irradiation for Hodgkin's disease. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  L. Constine,et al.  Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. , 1997, International journal of radiation oncology, biology, physics.

[38]  A. Hagenbeek,et al.  Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  A. Hoes,et al.  Prevalence of stroke in the general population. The Rotterdam Study. , 1996, Stroke.

[40]  W. Edwards,et al.  Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. , 1996, Human pathology.

[41]  J. Huisman.  The Netherlands , 1996, The Lancet.

[42]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[43]  P. Rubin,et al.  Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. , 1996, International journal of radiation oncology, biology, physics.

[44]  F. Gherlinzoni,et al.  Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. , 1996, Haematologica.

[45]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[46]  B. Meunier,et al.  [Breast cancer after treatment of Hodgkin's disease]. , 1995, Journal de gynecologie, obstetrique et biologie de la reproduction.

[47]  C. de Wolf‐Peeters,et al.  EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  K. A. Lee,et al.  Analysis of the p53 gene, its expression and protein stabilization in non-Hodgkin's lymphomas. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[50]  S L Hancock,et al.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.

[51]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[52]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[53]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[54]  M. van Glabbeke,et al.  Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[56]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[57]  W. Roberts,et al.  Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. , 1981, The American journal of medicine.

[58]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[59]  Références , 2022, Revue annuelle du marché des produits forestiers 2019-2020.

[60]  D.,et al.  Regression Models and Life-Tables , 2022 .